STADOL (butorphanol tartrate) by Bristol Myers Squibb is mechanism of action butorphanol is a partial opioid agonist at the mu opioid receptor and a full agonist at the kappa opioid receptor. Approved for pain severe enough to require an opioid analgesic, for which alternative treatments are inadequate. First approved in 1978.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
STADOL (butorphanol tartrate) is an injectable opioid analgesic approved in 1978 for moderate-to-severe pain when alternative treatments are inadequate. It functions as a partial agonist at mu opioid receptors and a full agonist at kappa receptors, producing analgesia through CNS opioid receptor modulation. The drug is administered via injection and is indicated for patients requiring opioid-level pain relief.
With LOE approaching and moderate competitive pressure (30/100), the brand team faces transition planning; headcount stability expected but growth limited.
Mechanism of Action Butorphanol is a partial opioid agonist at the mu opioid receptor and a full agonist at the kappa opioid receptor. The principal therapeutic action of butorphanol is analgesia. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions,…
Worked on STADOL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on STADOL offers limited growth prospects given its LOE-approaching lifecycle and legacy status; however, roles in this space provide deep expertise in opioid management, specialty distribution, and regulatory compliance in a highly controlled environment. Career advancement is more likely through lateral movement to growth-stage products or into specialized opioid governance roles rather than vertical promotion within the brand.